Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 14, Issue 7, Pages 1815-1819Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1445947
Keywords
genital warts; imiquimod; early protein 7; interleukin 10
Categories
Funding
- Science and Technology Research program of Foshan city [2012AA100461]
- Foshan City Council Research Platform Fund [2015AG1003]
- Science and technology Department of Guangdong province [2012B03180003]
- National Natural Science Foundation of China [81472451]
- Science and Technology Research program of Guangdong province [2016A020213001]
- first affiliated hospital of Guangdong Pharmaceutical University
Ask authors/readers for more resources
Genital warts are one of the most common sexually transmitted diseases worldwide. The disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 and 11. Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (polyphenon E) ointment to the warts. However, low patient compliance and high recurrence rate are significant problems for the treatment of genital warts by imiquimod and ablative therapies. We summarise recent literature in this area and propose combining imiquimod with other therapies to increase the efficacy of imiquimod.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available